oral glp 1 in development GLP-1: how to win the next GLP-1 era A timeline of GLP- 1

Afamelanotide received EMA approval in Europe (2014) and FDA approval in the United States (2019) for EPP making it the only melanocortin peptide to reach full regulatory approval to date

Lu quan trng khi s dng L-glutathione v glutathione: Glutathione v L-glutathione dng ht gy ra cc vn v h hp mt s ngi b hen suyn nh

CagriSema (the combination) was submitted for FDA approval in December 2025, but cagrilintide on its own is earlier in the process

And comparing them meaningfully is harder than it looks - the differences that actually matter aren't the ones the marketing pages lead with

This seemingly small change has a massive impact: Increased Potency: It increases its potency by up to 10x in certain tissues

B.FarzanM.ChenB.ChoeH